Clinical Trials Sponsored by Salient Pharmaceuticals Incorporated

Total 291 results

Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

Epilepsy

United States, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom, Canada, Germany, Australia, France, Italy, Czechia, Austria, Greece, Sweden
Vertex Pharmaceuticals Incorporated

Terminated

Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Cervical Spinal Cord Injury

United States, Canada
Vertex Pharmaceuticals Incorporated

Approved for marketing

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France
Sound Pharmaceuticals, Incorporated

Unknown

A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL)

Noise Induced Hearing Loss

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Cystic Fibrosis

United States, Australia, Canada, Germany, Switzerland, Israel, Netherlands, Belgium, Italy, United Kingdom, France
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada, France, Spain, Israel, Australia, Austria
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Cystic Fibrosis

United States, Canada, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Australia, Denmark, Canada, Sweden
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, France, Spain, Belgium, Canada, Austria, Australia, Germany, United Kingdom, Denmark
Sound Pharmaceuticals, Incorporated

Completed

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Cancer | Hearing Loss

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Estonia, Lithuania, South Africa
Vertex Pharmaceuticals Incorporated

Completed

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Rheumatoid Arthritis

United States, Argentina, Bulgaria, Czech Republic, Estonia, Germany, Hungary, Mexico, Poland, Romania, Russian Federation, Serbia, Slovakia, Ukraine
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Australia, New Zealand, Belgium
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Terminated

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Hepatitis C

Canada, United States
Vertex Pharmaceuticals Incorporated

Completed

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Chronic Hepatitis C

United States
Acetylon Pharmaceuticals Incorporated

Completed

Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects

Healthy

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 1, QT/QTC Interval Study in Healthy Subjects

Cystic Fibrosis

Netherlands
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Chronic Hepatitis C

Austria, France, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Chronic Hepatitis C Virus

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Terminated

VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer

Lung Cancer

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects

Drug Interactions

United States
Vertex Pharmaceuticals Incorporated

Completed

A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Poland, Belgium, Romania, Serbia, United States, Puerto Rico, Germany, Hungary, Russian Federation, Croatia
Vertex Pharmaceuticals Incorporated

Completed

Trial of AVN-944 in Patients With Advanced Hematologic Malignancies

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Waldenstrom's Macroglobulinemia | Acute Leukemia | Chronic Leukemia

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-985 in Subjects With Chronic Hepatitis C

Chronic Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 on Desipramine

In Development for Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

Healthy

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of Telaprevir in Subjects With Hepatic Impairment

Hepatic Insufficiency

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Pain

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada, Australia
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

Renal Impairment

United States
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Diabetic Peripheral Neuropathy

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

Pain

Australia

3

Subscribe